Breakthrough for Overcoming Lymph Edema

Breakthrough for Overcoming Lymph Edema - BTOLE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004292

Enrollment

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph edema

Interventions

cilostazol 6 months 200 mg/2x aspirin 6 months 100 mg/1x

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese adult with lymph edema

Exclusion criteria

Exclusion criteria: 1, cancer carriers 2, patients with remarkable hemorrhage 3, patients with tachycardia or severe ischemic heart disease 4, patients who already took aspirin or cilostazol

Design outcomes

Primary

Measure	Time frame
Grade of edema (circumference and subcutaneous area of deseased limb on CT)	—

Secondary

Measure	Time frame
Pain (VAS), Grade of lymph congestion (lymph scintigraphy), Skin perfusion pressure	—

Countries

Japan

Contacts

Public ContactNaomi Tanuma

National Center for Global Health and Medicine Medical Research Management Office

shinzou.gimu@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026